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Abstract Peroxisome proliferator-activated receptor (PPAR) Q
was shown to be required for adipocyte formation both in vivo
and in vitro. However, the role of PPARQ in the initial steps of
adipose cell development was not distinguished from its role in
the terminal steps. We now show that PPARQ is expressed early
in embryoid bodies (EBs) derived from embryonic stem cells and
in E.8.5 mouse embryos. Addition of a specific ligand for PPARQ
in developing EBs over-expressing PPARQ did not commit stem
cells towards the adipose lineage. In differentiated PPARQ3=3
EBs, only markers characteristic of preadipocytes were found to
be expressed. PPARN is present in EBs but did not compensate
for the lack of PPARQ in terminal differentiation. Taken
together, these results favor a critical PPARQ-independent phase
culminating in preadipocyte formation that precedes a PPARQ-
dependent phase in the development of adipose cells from
pluripotent stem cells. ß 2002 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
Key events of terminal di¡erentiation converting preadipo-
cytes into mature lipid-¢lled adipocytes have been character-
ized in recent years. However, the molecular mechanisms reg-
ulating the early development of adipose cells are poorly
understood, and master genes that commit the progression
from stem cells to the adipoblast stage of development have
not yet been identi¢ed. The best-characterized transcriptional
regulators involved in the development of mature adipocytes
are members of the peroxisome proliferator-activated receptor
(PPAR) family of nuclear hormone receptors. PPARs are li-
gand-activated transcription factors that bind as heterodimers
with members of the retinoid X receptor (RXR) subfamily to
PPAR-responsive elements (PPREs) in the promoters of re-
sponsive genes. Three subtypes, PPARK, PPARN and PPARQ,
have been identi¢ed. PPARQ is highly expressed in adipocytes
and several lines of evidence, ¢rst obtained in vitro, indicate
that PPARQ plays an important role in adipogenesis. Treat-
ment of preadipocytes with PPARQ ligands dramatically in-
creases terminal di¡erentiation, and forced ectopic expression
of PPARQ in a variety of mesenchymal cells is su⁄cient to
induce adipogenesis [1]. The requirement of PPARQ in the
development of fat cells has recently been investigated in
vivo by gene targeting [2^4]. Homozygous PPARQ-de¢cient
embryos die at midgestation due to a placental defect associ-
ated with myocardial thinning [2]. This phenotype revealed a
new role of PPARQ in the development of placenta, but pre-
cluded a straightforward approach to investigating the role of
PPARQ in the development of adipose tissue. Blastocyst in-
jection of PPARQ3=3 embryonic stem (ES) cells showed that
these mutant cells did not contribute to the formation of
adipose tissue in chimeric animals [4]. Although these studies
showed convincingly that PPARQ is required for the forma-
tion of lipid-containing cells in vivo, it did not investigate the
role of PPARQ in earlier events relative to adipose cell deter-
mination, nor did it indicate at what stage PPARQ3=3 cells
were blocked in the adipocyte developmental program. To
address this issue, the role of PPARQ during the development
of ES cells in vitro has been investigated.
ES cells are derived from the inner cell mass of 3.5 day
blastocysts [5,6]. It is well documented that formation of em-
bryoid bodies (EBs) permits the commitment of pluripotent
ES cells into multiple cellular lineages in vitro [7]. The di¡er-
entiation of ES cells can mimic closely the development of
early embryos in vivo [8]. Therefore, in vitro di¡erentiation
of ES cells provides an invaluable model both for studying the
early steps of development and for the characterization of the
role of genes expressed during di¡erent developmental pro-
grams. We have shown previously that ES cells can di¡eren-
tiate with a high e⁄ciency into fat cells [9^11]. A prerequisite
for the commitment of ES cells into the adipose lineage was
the treatment of ES cell-derived EBs at an early stage of their
di¡erentiation with all-trans retinoic acid (RA). Two phases of
adipogenesis were identi¢ed. The ¢rst phase, between day 2
and day 5 after EB formation, consisted of the maintenance of
ES cell-derived EBs in suspension and treatment with RA. At
this stage EBs contained di¡erentiating cells of ectodermal,
endodermal and mesodermal lineages [12]. The second phase
consisted of the plating of the RA-treated EBs, which results
in the development of di¡erentiated embryonic (DE) out-
growths. The percentage of DE outgrowths containing adipo-
cyte colonies was found to be modulated by adipogenic hor-
mones.
In the studies presented herein, we showed that PPARQ was
expressed early in developing EBs and in E 8.5 embryos. A
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possible role of PPARQ in the initial step(s) of adipose cell
commitment was examined in ES cells over-expressing PPARQ
as well as in PPARQ-de¢cient ES cells. The results indicate
that there is a PPARQ-independent phase in which the cells
are committed towards the adipogenic lineage, followed by a
PPARQ-dependent phase which is critical for the formation of
mature lipid-¢lled adipose cells from pluripotent stem cells.
2. Materials and methods
2.1. Embryos, ES cell culture and di¡erentiation of EBs
Procedures involving animals conformed to institutional and Fed-
eral guidelines and were approved by the appropriate institutional
review boards. Matings were established between C57BL/6J mice
(Jackson Laboratories, Bar Harbor, ME, USA). CGR8 ES cells [13]
were cultivated in the pluripotent state on gelatin-coated plates as
previously described [9]. D3 ES cells and PPARQ3=3 ES cells were
cultivated in undi¡erentiated state on a feeder layer of mitomycin C-
inactivated STO cells. Before EB formation, cells were grown on
gelatinized plates as described for CGR8 ES cells. The experimental
protocol used for di¡erentiation of ES cells into adipocytes has been
described previously [9]. Commitment of ES cells into the adipose
lineage was initiated by all-trans RA treatment. Five-day-old EBs
were then plated onto culture plates to allow development of DE cells
as outgrowths. Adipocyte di¡erentiation in outgrowths was enhanced
by adding 85 nM insulin, 2 nM triiodothyronine (T3) and the thia-
zolidinedione BRL49653 and CD3986 when indicated. BRL49653 was
a gift from SmithKline Beecham and CD3986 was a gift from Gal-
derma (Sophia-Antipolis, France).
2.2. Plasmid constructs
To generate the PPARQ expressing vector, a 1.5-kb XhoI/NotI frag-
ment containing the complete open reading frame of mouse PPARQ
was inserted into the pCAGSIH vector in place of the alkaline phos-
phatase cDNA fragment. Therefore, the PPARQ expressing vector
consisted of the synthetic CAG promoter [14] driving the PPARQ-
IRES-hygromycin resistance bicistronic gene. This vector was appro-
priate for gain of function experiments in ES cells as it showed the
following features: (i) the CAG promoter has been proven to be
e⁄cient in undi¡erentiated ES cells and in di¡erentiated derivatives
([15] and this paper) and (ii) the bicistronic gene ensured expression of
PPARQ in all stably transfected cells. This assumption has been veri-
¢ed in preliminary experiments (not shown). A polyclonal cell popu-
lation, containing 10^20 clones, was generated and used for all experi-
ments, avoiding therefore the use of individual clones. The pCAGSIH
vector was constructed in Austin Smith’s laboratory (CGR, UK) and
was also used to generate the control-ES cell population.
2.3. Generation of transgenic ES cell lines and transactivation assays
CGR8 ES cells were transfected with pCAG/PPARQ and pCAGSIH
expressing vectors using the FuGene 6 transfection system (Roche
Molecular Biochemicals) according to the manufacturer’s protocol.
Clones were selected in hygromycin (100 Wg/ml) for 10 days and
pooled to generate polyclonal cell populations. For determination of
the capacity of transactivation of PPARQ in control-ES cell and
PPARQ-ES cell populations, cells were stably co-transfected with the
PPREx3-tk-¢re£y luciferase (luc) reporter and a neomycin resistance
gene expressing vector. Clones were selected in G418 (200 Wg/ml) for
10 days and pooled. The PPREx3-tk-¢re£y luc reporter contained
three copies of the PPRE from the acyl-CoA oxidase promoter [16].
Fire£y luciferase activities in EBs (pool of 200 EBs) were determined
using the Bright-Glo Luciferase Assay System (Promega, France).
Results were normalized with the protein concentrations determined
by the Bio-Rad Protein Assay.
2.4. RNA analysis
RNA from embryos was isolated using guanidinium thiocyanate
and cesium chloride gradients. Random hexamer-primed cDNA was
prepared from 1 Wg of total RNA. PCR used the following oligonu-
cleotides: PPARQ, forward 5P-CGAGTCTGTGGGGATAAAGC-3P ;
reverse 5P-CAGCGGGAAGGACTTTATGT-3P ; L-actin, forward 5P-
TGGAATCCTGTGGCATCCATGAAAC-3P, reverse 5P-TAAAAC-
GCAGCTCAGTAACAGTCCG-3P. PCR conditions were 95‡C for
5 min followed by 36 cycles of 94‡C for 30 s, 57‡C for 30 s and
72‡C for 40 s. Samples were then heated at 72‡C for 10 min and
analyzed. RNA from EBs was prepared as previously described [17].
For reverse transcription (RT)-PCR analysis, samples of 500 ng were
reverse-transcribed and cDNAs were ampli¢ed using the OneStep RT-
PCR kit (Qiagen, Germany). RT reactions were denatured for 15 min
at 95‡C, followed by 40 cycles of 1 min denaturation at 94‡C, 1 min
annealing at 55‡C and 1 min elongation at 72‡C. Primers for PPARQ
and hypoxanthine guanine phosphoribosyl transferase (HPRT) were
included in the same reaction. Sequences of primers used in PCR are
as follows: PPARQ, 5P-GAATGACCAAGTGACTCTGCTCAA-3P
and 5P-CAAGCTGAATCACCCAGAGTCC-3P ; HPRT, 5P-GCT-
GGTGAAAAGGACCTCT-3P and 5P-CACAGGACTAGAACACC-
TGC-3P. Electrophoretic separation of PCR products was carried out
on 2% agarose gels. Northern blot analysis was performed as previ-
ously described [9]. Quanti¢cation of the hybridization signal was
performed using a PhosphorImager apparatus (Fujix Bas 1000)
coupled to the MacBas ver2.x bio-imaging analyzer. The Brachyury
cDNA was obtained from Dr. B. Herrmann (Max-Planck Institut,
Freiburg, Germany). The HMGIC cDNA was generated by RT-
PCR using RNA prepared from EBs. Sequences of primers and
PCR conditions are described in [18].
Fig. 1. Expression of PPARQ in EBs derived from ES cells and in
embryos. A: 20 Wg of total RNA was prepared at indicated times
and the expression of marker genes was determined by Northern
blotting. The results of a representative experiment are shown and
are expressed by taking as 100% the maximal signal obtained for
each probe. B: Total RNA extracted from pluripotent undi¡erenti-
ated ES cells (ES) or from EBs at the indicated times was reverse-
transcribed and PCR-ampli¢ed using primers speci¢c for PPARQ
and the housekeeping gene HPRT. PCR-ampli¢ed fragments sepa-
rated by electrophoresis and stained with ethidium bromide are
shown. Cont.: control with no RNA. C: Whole cellular RNA was
prepared from embryos at indicated times. 1 Wg was reverse-tran-
scribed using random hexamer-primed cDNA. 5% of the cDNA re-
action product was ampli¢ed using PPARQ- and L-actin-speci¢c
primer pairs. RNA prepared from PPARQ3=3 EBs was used as a
negative control.
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3. Results and discussion
3.1. Generation of a polyclonal ES cell population
over-expressing PPARQ
We have investigated the expression of the endogenous
PPARQ gene during in vitro development of ES cells. Its pat-
tern of expression was compared with that of developmental
marker genes such as Brachyury T, a marker of nascent mes-
oderm [19], HMGIC, a gene preferentially expressed in undif-
ferentiated mesenchymal cells [20], highly expressed in 3T3-L1
preadipocytes [21] and in adipose tissue [18], and ALBP, an
adipocyte di¡erentiation-dependent gene [22]. As shown in
Fig. 1A, the Brachyury T gene was speci¢cally expressed in
EBs and corresponded with the permissive period for adipo-
genic commitment which was de¢ned previously [9]. Expres-
sion of Brachyury T gene in early di¡erentiating EBs has
previously been reported [12]. Expression of the HMGIC
gene was weak in EBs and peaked early in DE outgrowths
at a time when undi¡erentiated mesenchymal cells were pro-
liferating. Its expression declined thereafter when various ter-
minally di¡erentiated cell types appeared, such as adipose cells
characterized by the expression of ALBP. Expression of PPARQ
was detected by Northern blotting only in DE outgrowths and
paralleled the expression of ALBP. However, the greater sen-
sitivity of RT-PCR showed that PPARQ was also expressed in
EBs during the permissive period for adipogenic commitment
(Fig. 1B). In mouse embryos, PPARQ expression was detected
by RT-PCR at gestation day 8.5 and beyond (Fig. 1C). To
gain insights into the capacity of PPARQ to commit stem cells
into the adipogenic lineage and to study its role in the di¡er-
ent steps of adipose cell development, transgenic ES cells were
generated. Cells of the pluripotent ES cell line CGR8 were
stably transfected with a pCAG/PPARQ-IRES-hygromycin bi-
cistronic expression vector. A polyclonal cell population,
named PPARQ-ES cell population, was isolated. A polyclonal
cell population, named control-ES cell population expressing
an irrelevant cDNA, was also generated (see Section 2). Ex-
pression of PPARQ transgene in early EBs was detected by
Northern blotting. RXRK, the partner of PPARQ required to
form functional heterodimers, was expressed at a similar level
in control and PPARQ over-expressing EBs (Fig. 2A). The
PPARQ transgene had the capacity, in 5-day-old EBs, to reg-
ulate the transcription of PPRE-¢re£y luciferase gene under
the control of a PPRE. As shown in Fig. 2B, stimulation with
a speci¢c PPARQ ligand, the thiazolidinedione BRL49653 [23],
led to detectable luciferase activity in transgenic ES cells only.
All-trans RA enhanced transcriptional activity of PPARQ and
activation of RXRs by the 9-cis RA had the same e¡ect as the
all-trans RA. Addition of both BRL49653 and all-trans RA or
9-cis RA led to a higher PPARQ transcriptional activity as
expected. Stimulation of EBs with a speci¢c ligand of PPARN,
the CD3986 also known as GW2433 [24], led to a similar
increase in expression of luciferase activity in wild-type and
PPARQ-ES cells. This result is in agreement with our previous
data showing expression of PPARN in early EBs [9]. Alto-
gether, these results indicated that the intracellular environ-
ment in EBs was appropriate for the transgene to activate the
transcription of target genes. Therefore, it was possible to
study the e¡ect of activation of the transgene PPARQ on the
development of adipose cells.
3.2. E¡ect of PPARQ during the development of DE outgrowths
EBs formed from PPARQ- and control-ES cells were treated
with RA to commit them into the adipose lineage. The thia-
zolidinedione BRL49653 was then added during the phase of
di¡erentiation and expression of speci¢c genes for adipocytes,
namely ALBP and glycerol-phosphate dehydrogenase
(GPDH), was investigated by Northern hybridization analy-
sis. ALBP and GPDH gene expression was increased 2.8 þ 0.4-
fold and 3.5 þ 0.8-fold respectively in PPARQ-DE outgrowths
compared to control-DE outgrowths (in four independent ex-
Fig. 2. A: Expression of PPARQ transgene and RXRK in control
and PPARQ over-expressing EBs. RNAs were prepared from 5-day-
old EBs and 20 Wg was subjected to Northern blot analysis.
B: Transcription of a PPRE-containing gene in control-ES cells and
PPARQ-ES cells stably transfected with PPREx3-tk-¢re£y luciferase
reporter gene. Luciferase activities were determined 4 h after addi-
tion of 1: 0.1% DMSO; 2: 1 WM PPARN ligand CD3986; 3: 1 WM
PPARQ ligand BRL49653; 4: 1037 M all-trans RA; 5: RA+BRL;
6: 1036 M 9-cis RA or 7: 9-cis RA plus BRL. Activity was normal-
ized versus protein content. The values represent mean þ S.E.M. of
three independent experiments.
Fig. 3. E¡ects of over-expression and activation of PPARQ in DE
outgrowths. A: EBs, formed from control-ES cells (C) and PPARQ-
ES cells (P) were stimulated from day 2 to day 5 with either 0.1%
DMSO (which is the vehicle of RA) or 0.1 WM RA. After plating,
DE outgrowths were maintained in medium supplemented with
1 WM BRL49653. B: PPARQ-DE outgrowths were maintained in
di¡erentiation medium in the absence (0) or presence of 0.5 WM
BRL49653 for the indicated period. Total RNA was prepared at
day 20 and 20 Wg was subjected to Northern blot analysis.
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periments, see Fig. 3A, right panel). In the absence of RA
treatment during the critical period for commitment, expres-
sion of the ALBP and GPDH genes remained very low, if
detectable at all (Fig. 3A, left panel). These data indicated
that RA remained necessary for promoting the initial steps
of development of adipose cells despite forced PPARQ expres-
sion. Altogether, these results showed that over-expression
and activation of PPARQ during the di¡erentiation phase of
embryonic cells derived from RA-treated EBs led to an en-
hancement of adipogenesis. Interestingly, the activation of
PPARQ in DE outgrowths at earlier time than day 10 had
no e¡ect on the degree of adipocyte di¡erentiation at day
20. As shown in Fig. 3B, exposure of PPARQ-DE cells to
BRL496543 from day 3 or from day 10 led to the same e¡ect
on adipocyte di¡erentiation at day 20 as marked by the ex-
pression of ALBP gene. A similar pattern of expression was
obtained for the GPDH gene (not shown). Exposure of
PPARQ-DE cells to BRL49653 from day 7 to 10 had no e¡ect
on adipocyte di¡erentiation at day 20 and exposure from day
10 was su⁄cient to achieve maximal response on adipogenesis
at day 20 (not shown). These observations con¢rmed that
PPARQ had a major role in terminal di¡erentiation-related
events and suggested that it played no role in the early steps
of adipose cell development. We next con¢rmed this hypoth-
esis by activating PPARQ during the determination phase of
di¡erentiation.
3.3. Consequences of activation of PPARQ in EBs on the
development of adipose cells
PPARQ-EBs were stimulated from day 2 to day 5 either
with RA or BRL49653 and adipogenesis in 20-day-old DE
outgrowths was scored. Treatment with RA (1038 M or
1037 M) led to a high level of adipogenesis as expected. In
contrast, activation of PPARQ alone did not promote commit-
ment to the adipose lineage whereas treatment with RA plus
BRL49653 did not increase adipogenesis compared to RA
only (Fig. 4A). Activation of PPARQ together with RXRs
was ine⁄cient in promoting adipogenesis (not shown). These
results indicated that in the absence of RA the full activation
PPARQ was not able to commit stem cells into the adipogenic
lineage. We next analyzed expression of adipocyte di¡erentia-
tion-dependent genes. As shown in Fig. 4B, expression of
ALBP and GPDH genes was high in DE outgrowths derived
from RA-treated EBs. No further increase (1.2 þ 0.3-fold from
six independent experiments) was observed after the simulta-
neous addition of RA and BRL49653 (Fig. 4B, lane 2) where-
as their expression remained low in DE outgrowths derived
from both BRL49653-treated and untreated EBs (Fig. 4B,
lanes 3 and 4 respectively). Expression of HMGIC and lipo-
protein lipase (LPL) genes, two markers expressed in preadi-
pocytes earlier than ALBP and GPDH, was not modi¢ed by
activation of PPARQ in early EBs (not shown) suggesting that
early expression of PPARQ did not lead to the generation of
preadipocytes which were blocked prior to terminal di¡eren-
tiation. Altogether, these results demonstrated that activation
of PPARQ could not act as a substitute for the promoting
e¡ect of RA on the determination of stem cells towards the
adipose lineage and that PPARQ did not play a role in the
initial steps of the adipose cell development.
3.4. PPARQ3=3 ES cells treated with RA can be committed
into the adipose lineage but are blocked at the
preadipose stage of the developmental program
Recently, PPARQ3=3 ES cells have been generated and it
was shown that they failed to undergo di¡erentiation into
adipocytes both in vitro and in vivo. Normal levels of expres-
sion of C/EBPL and C/EBPN in PPARQ null ES cells suggested
that mutant cells were arrested at the preadipose stage [4].
C/EBPL and C/EBPN are two genes expressed in preadipo-
cytes but also expressed in other cell types present in wild-
type and mutant di¡erentiating ES cells. Therefore, this result
did not indicate whether the lack of PPARQ was preventing
commitment of stem cells towards the adipose lineage or
Fig. 5. Expression of di¡erentiation markers in di¡erentiating con-
trol- and PPARQ3=3 ES cells. A: EBs, formed from D3 ES cells
(WT) and from PPARQ-de¢cient ES cells (3/3), were treated with
RA as shown in Fig. 3. RNA was prepared at indicated times.
Data represent the average of two experiments and are expressed by
taking as 100% the maximal signal obtained for each probe. B: EBs
were treated as in A and supplemented (+) or not (3) with 1 WM
CD3986 from day 7 to 17. Total RNA was prepared at day 17 and
20 Wg was subjected to Northern blot analysis.
Fig. 4. Lack of e¡ects of PPARQ during the commitment period of
ES cells. A: EBs were treated between days 2 and 5 with 1037 M
or 1038 M RA in the presence or in the absence of 1 WM
BRL49653. Then, DE outgrowths were maintained in medium sup-
plemented with 1 WM BRL49653. The percentage of 20-day-old DE
outgrowths containing adipocyte colonies was determined. The num-
ber of DE outgrowths examined was between 80 and 120 for each
condition. Data were the means from two experiments. B: RNA
was prepared from 20-day-old DE outgrowths derived from
PPARQ-EBs treated either with 1: 0.1 WM RA; 2: 0.1 WM RA plus
1 WM BRL49653; 3: 1 WM BRL496543; 4: 0.1% DMSO.
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whether they were blocked at the preadipose stage. To address
this issue, the expression of HMGIC and LPL genes in RA-
treated wild-type and PPARQ-de¢cient DE outgrowths was
investigated. As previously indicated, HMGIC expression is
high in preadipocytes and does not persist in adipocytes [18].
LPL is preferentially expressed in adipose tissue and we have
previously shown that during adipose cell di¡erentiation, the
emergence of LPL characterizes the preadipose stage, its ex-
pression being increased during terminal di¡erentiation
[25,26]. LPL gene is also expressed in skeletal myocytes, but
as we have previously reported, di¡erentiation of ES cells into
adipocytes inhibits the development of skeletal myocyte line-
age [10]. Therefore, studies on the expression of both genes
were appropriate for investigating the stage at which adipose
cell development was blocked in mutant cells. As shown in
Fig. 5A, the kinetics of expression of both preadipocyte
markers were paralleled in wild-type and di¡erentiating mu-
tant cells, strongly suggesting that the lack of PPARQ did not
prevent commitment of stem cells into the adipose lineage but
led to an arrest at the preadipose stage of the developmental
program. The increased expression of the LPL gene at day 12
in wild-type cells re£ected the appearance of mature adipo-
cytes.
It has recently been reported that ectopic expression of
PPARN in ¢broblasts promotes expression of adipocyte-spe-
ci¢c genes [27]. In addition, over-expression of PPARN in
Ob1771 and 3T3-F442A preadipose cells enhances this pro-
cess [27,28]. As shown in Fig. 5B, PPARN was expressed in
wild-type and mutant di¡erentiating outgrowths. However, its
stimulation with the speci¢c agonist CD3986 was clearly un-
able to compensate for the lack of PPARQ in terminal di¡er-
entiation of ES cells to adipocytes, as mutant DE outgrowths
did not contain adipocytes (not shown) and were not able to
express the ALBP gene either with or without stimulation
(Fig. 5B). These results indicate that, although PPARQ was
not required for the initial steps of adipose cell development,
it plays a crucial role in terminal steps of di¡erentiation and
that this role could not be replaced by PPARN.
In conclusion, a model is proposed in which, in contrast to
PPARQ-dependent di¡erentiation of preadipocytes into adipo-
cytes, commitment of pluripotent stem cells to the adipose
lineage is independent of PPARQ. Altogether, our results in-
dicate that expression of PPARQ is not rate-limiting in trigger-
ing the adipose lineage from pluripotent stem cells. However,
one cannot exclude that endogenous ligands and target mol-
ecules of PPARQ, which are not fully identi¢ed, represent the
rate-limiting step of the process controlled by RA. Further
analysis of this possibility requires the characterization of
such ligands. Regulation of adipocyte di¡erentiation is an
important process if one considers the need to control the
development of adipose tissue. The increase in weight of adi-
pose tissue in obesity is due to hypertrophy of fat cells and an
increase of the recruitment of new adipocytes from precursors.
So far, RA is the only e¡ector able to promote the ¢rst steps
of adipose cell development. A better understanding of the
molecular mechanisms mediating RA e¡ects in early di¡eren-
tiating ES cells and the isolation of RA-speci¢c target genes
should lead to the identi¢cation of the regulatory genes in-
volved in adipocyte determination.
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